Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

NCT03668613 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Chronic Plaque-type Psoriasis

Interventions

DRUG: secukinumab low dose
DRUG: secukinumab high dose

Sponsor

Novartis Pharmaceuticals